source
- Incyte reports lasting tumor responses in pancreatic cancer patients using targeted drug plus chemotherapyIncyte announced at the European Society for Medical Oncology meeting that its targeted therapy, when combined with standard chemotherapy, produced durable tumor responses in a subset of pancreatic…
- Moderna CEO Bancel optimistic after Phase 3 success of mRNA melanoma vaccine intismeranModerna chief executive Stéphane Bancel said the company will move quickly to obtain FDA approval for its experimental melanoma therapy intismeran after a Phase 3 trial showed positive results. Th…